MarketInOut Stock Screener Log In | Sign Up

Nasus Pharma Ltd

NYSE • Healthcare • Drug Manufacturers - General • Quote as of 10/30/2026
Nasus Pharma Ltd stock price and volume chart

Company Profile

IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeNYSE
Market Capitalization38.89 mln
Float5.95 mln
Earnings Date11/30/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

29 / 100
Underperforming

Debt / Equity

0.01
Debt-free

ROE

-307
Deeply negative

ROA

-169
Deeply negative

Business Description

Nasus Pharma Ltd. is an Israeli pharmaceutical company founded in 2019 and headquartered in Tel Aviv, focused on developing nasal spray medicines for life-threatening emergencies. Its two lead products are a nasal spray version of epinephrine for treating severe allergic reactions and a nasal powder spray of naloxone for reversing opioid overdoses. The company's approach aims to make critical emergency treatments faster and easier to administer.

Key Fundamentals

EPS-1.20
ROE-307
ROIC-633
ROA-169
EBITDA, mln-3.35
EV / EBITDA-11.11
EV / EBIT-11.11

Quote Details

Last 3.07
Change -0.12 (-3.76%)
Open 3.23
Volume 4,889
Turnover 15,009
Average Volume 17,712

Financial Ratios

Leverage Ratio1.13
Current Ratio8.77
Price / Book11.59
Price / Tangible Book11.59
Debt / Equity0.01

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio4.24
Short % of Float1.19

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -12.03% 8 / 100   
1 Month -19.63% 19 / 100   
2 Months -0.65% 55 / 100   
6 Months 11.64% 85 / 100   
1 Year -60.39% 15 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog